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S U M M A R Y
Objectives: Severe enterovirus 71 (EV71) infections in children can result in acute heart failure. B-type
natriuretic peptide (BNP) is a good biomarker of myocardial stress. The purpose of this study was to use
plasma BNP for the detection of EV71 infection with cardiac involvement.
Methods: Patients with severe EV71 infections and healthy control subjects were studied: group 1
(n = 30), normal controls; group 2 (n = 20), EV71 infection with central nervous system involvement; and
group 3 (n = 3), EV71 infection with cardiopulmonary failure. The demographic and laboratory data
including plasma BNP levels were analyzed statistically.
Results: All group 2 patients recovered completely without neurological sequelae, and all group 3
patients survived without cardiac complications. Group 3 patients had higher troponin I, MB fraction of
creatine kinase, and BNP levels than patients of the other groups. The median BNP values were <5 pg/ml
in group 1, 9.5 pg/ml in group 2, and 238 pg/ml in group 3. Using a BNP cut-off value of 100 pg/ml to
identify cases with severe EV71 infection and acute heart failure, the sensitivity and speciﬁcity were both
100%.
Conclusions: Children with severe EV71 infections have varying degrees of myocardial stress. Plasma
BNP would be a sensitive and reliable biomarker for the detection of cardiac involvement in children
with severe EV71 infections.
 2013 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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Severe enterovirus 71 (EV71) infections are unusual during an
epidemic of EV71, but they may result in high morbidity and
mortality.1–3 Most children with EV71 infections present with
hand, foot, and mouth disease (HFMD) or herpangina, and less than
0.01% of children with EV71 infections develop more serious
symptoms such as central nervous system (CNS) manifestations,
pulmonary edema, acute heart failure, rapid shock, or even
death.4–6 Acute cardiac dyskinesia, low ejection fraction (EF),
and regional wall motion abnormalities of the left ventricle
detected by echocardiography have commonly been noted in
EV71-related early mortality.6–8 Therefore, acute heart failure with
or without pulmonary edema has been proposed as the main cause
of rapid deterioration leading to EV71-related early mortality.* Corresponding author. Tel.: +886 4 23741259.
E-mail address: sljan@vghtc.gov.tw (S.-L. Jan).
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http://dx.doi.org/10.1016/j.ijid.2013.06.012B-type natriuretic peptide (BNP), which is also called brain-type
natriuretic peptide, was ﬁrst described in 1988 after its isolation
from porcine brain.9 However, it was soon found to originate
mainly from the heart, representing a cardiac hormone secreted
predominantly from the ventricular myocardium.10 The main
stimulus for increased BNP synthesis and secretion is myocardial
wall stress caused by excessive volume or pressure loading of the
heart.11,12 In clinical application, BNP has been thought to be a
sensitive and speciﬁc biomarker of ventricular dysfunction and
heart failure. Correlations between elevated plasma BNP concen-
trations in patients with heart failure and the severity of heart
failure symptoms have been found to predict hospital readmission
and mortality, and increased during different types of myocardial
overload.11–20.
There is now increasing interest in BNP, not only in adults with
heart failure, but also in pediatric patients with cardiovascular
diseases such as congenital heart disease, critical heart disease, and
Kawasaki disease.13–20 In the pediatric age group, BNP can be
measured on commercial laboratory platforms and is now widely
used. However, the clinical application of plasma BNP remainsses. Published by Elsevier Ltd. All rights reserved.
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without acute heart failure.
The purpose of this pilot study was to determine plasma BNP
levels in the different stages of severe EV71 infection and to
establish a method of clinically applying plasma BNP in the
treatment of children with severe EV71 infection.
2. Materials and methods
2.1. Study population
Children younger than 7 years old with severe EV71 infections
who were admitted to the pediatric intensive care unit (PICU) of
Taichung Veterans General Hospital between April and July 2012
were enrolled in this study. Severe EV71 infections diagnosed
clinically were laboratory-conﬁrmed by the Taiwan Center for
Disease Control. The methods used to identify EV71 were the same
as those described by Fu et al.8 Thirty healthy children younger
than 7 years old constituted the control group. They visited the
outpatient clinics for heart murmur, chest pain, or allergic rhinitis.
A detailed history and complete physical examination were
conducted for each case. Functional murmur and non-cardiac
chest pain were conﬁrmed by clinical features and laboratory
studies, such as transthoracic echocardiography, chest X-ray, and
complete electrocardiogram. Children with allergic rhinitis re-
ceived echocardiography and a complete electrocardiogram to
exclude any cardiac problems. Written informed consent was
obtained from a parent for all children included in this study.
Patients who had genetic disorders, neuromuscular diseases,
craniofacial abnormalities, or previous cardiovascular diseases,
and those who could not participate for other reasons, were
excluded. The study cohort was divided into three groups: group 1
comprised normal controls, group 2 included patients who had
stage 2 EV71 infections, and group 3 included patients who had
stage 3 EV71 infections. In this study, two patients who were
suspected to have a stage 2 EV71 infection initially were excluded
due to negative results for EV71 in the laboratory conﬁrmation
study.
2.2. Staging of children with EV71 infection
According to a previous study on the staging of EV71 infection,3
the clinical features of EV71 infection can be divided into three
stages: HFMD/herpangina (stage 1) with oro-mucocutaneous
lesions only; CNS involvement (stage 2) with subtle neurologic
symptoms or signs such as drowsiness, limb weakness, ataxia, and
myoclonic jerks; and cardiopulmonary failure (stage 3) associated
with pulmonary edema/hemorrhage or acute decreased left
ventricular systolic function and shock. Severe EV71 infection
was deﬁned as an EV71 infection at or beyond stage 2.
2.3. Echocardiography
Echocardiography studies were performed using standard
techniques in accordance with the recommendations of the
Committee on M-mode Standardization of the American Society
of Echocardiography.21 All of the subjects received a complete
echocardiogram including M-mode, two-dimensional (2D) Dopp-
ler, and color Doppler echocardiograms. Left ventricular systolic
function was evaluated by EF and FS from M-mode and/or
Simpson’s rule by 2D echocardiography with a Sonos 5500 or 7500
ultrasound system (Philips, Andover, MA, USA). All echocardiogra-
phy studies were performed by an experienced echocardiographer
who was blinded to the results of the plasma BNP measurement.
2D echocardiography was done to assess the left ventricular wall
motion from different views. If regional wall motion abnormalitiesof the left ventricle existed, the left ventricular EF was measured by
biplane Simpson’s rule. Possible causes of ventricular dysfunction
such as anomalous origin of the left coronary artery from the
pulmonary artery and severe ventricular outﬂow obstruction were
excluded.
2.4. Plasma BNP measurement
A rapid, commercially available BNP ﬂuorescence immunoassay
(Triage Assay, Biosite Diagnostics, Inc., San Diego, CA, USA)
approved by the US Food and Drug Administration was used for
the BNP measurements in this study. For this point-of-care assay, a
venous blood sample was collected into an ethylenediaminete-
traacetic acid (EDTA) tube and was analyzed at room temperature
within 30 min of collection. BNP levels between 5 pg/ml and 5000
pg/ml can be measured using this kit, with an average inter-assay
coefﬁcient of variation of 3%. BNP standard deviation scores (SDS)
or z-scores were calculated according to the following formulas:
boys and girls aged 2 weeks to 10 years: BNP SDS = (natural
logarithm (ln) of BNP plasma level  2.05)/0.56; female patients
older than 10 years: BNP SDS = (lnBNP  2.32)/0.67; male patients
older than 10 years: BNP SDS = (lnBNP  1.80)/0.31.20 In this study,
blood was drawn from a peripheral vein or arterial line within 24 h
after being admitted to the PICU for patients with a severe EV71
infection diagnosed clinically and conﬁrmed by laboratory
methods later, for the determination of the plasma BNP level;
this was repeated if the disease progressed. In the control group,
blood was drawn from a peripheral vein soon after informed
consent was obtained.
2.5. Statistical analysis
Categorical variables were summarized as the median, mean 
standard deviation, or case numbers. Statistical analyses were
performed with SPSS version 15.0 for Windows (SPSS Inc., Chicago,
IL, USA). Comparisons of demographic data, laboratory features, and
echocardiography results between the study groups were analyzed by
Kruskal–Wallis test, one-way analysis of variance (ANOVA) with
post-hoc multiple comparison Scheffe´ test, or Mann–Whitney U-test
for continuous variables, and Pearson’s Chi-square test or the Chi-
square test for trends. Bars with different letters indicated signiﬁcant
differences between groups. Because of the different ages and sizes of
patients, the echocardiography parameters of left ventricular end-
diastolic and end-systolic internal dimensions (LVEDd and LVEDs)
were adjusted for body surface area for comparisons.22 Cut-off points
for receiver operating characteristic curve analyses, expressing
sensitivity, speciﬁcity, the positive predictive value (PPV), and the
negative predictive value (NPV), were determined. A p-value of <0.05
was considered statistically signiﬁcant.
3. Results
A total of 53 children (33 males and 20 females) with a mean
age of 2.5  1.7 years (range 0.5–6.8 years) were enrolled in this
study. The demographic data and laboratory features are shown in
Table 1. There were 30 healthy children (median 2.2 years) in group 1,
20 children (median 1.6 years) with EV71 stage 2 infections in group
2, and three children (median 3.0 years) with EV71 stage 3 infections
in group 3. There were no statistically signiﬁcant differences in
gender, age, body length, body weight, and body surface area among
the groups. There were no signiﬁcant differences in cardiothoracic
ratio calculated from the chest radiography, creatine kinase value, or
C-reactive protein level between group 2 and group 3, but patients in
group 3 had higher heart rate (p = 0.006), systolic blood pressure
(p = 0.028), MB fraction of creatine kinase (CK-MB) (p = 0.025), and
troponin I (p = 0.001) values than those in group 2. All patients in
Table 1
Demographic and laboratory features of all studied cohortsa
Group 1
(Control, n = 30)
Group 2
(EV71, stage 2, n = 20)
Group 3
(EV71, stage 3, n = 3)
p-Valueb
Gender 17M/13F 14M/6F 2M/1F 0.632
Age, years 2.5  1.0 (2.2) 2.3  2.4 (1.6) 3.6  2.1 (3.0) 0.056
Body length, cm 89  11 (87) 89  20 (84) 107  19 (97) 0.087
Body weight, kg 13.1  3.2 (12.7) 13.0  6.5 (10.7) 18.0  5.2 (15) 0.064
Body surface area, m2 0.57  0.10 (0.57) 0.56  0.19 (0.50) 0.73  0.16 (0.64) 0.086
Maximum heart rate, bpm 130  14 (133) 193  15 (195) 0.006
Maximum systolic blood pressure, mmHg 115  10 (111) 136  11 (137) 0.028
Echocardiography
Left ventricle end-diastolic internal dimension,c cm/m2 5.22  0.57 (5.20) 5.30  0.91 (5.49) 5.39  0.24 (5.42) 0.753
Left ventricle end-systolic internal dimension,c cm/m2 3.11  0.38 (3.16) 3.13  0.63 (3.08) 4.59  0.24 (4.55) 0.015
Ejection fraction (%) 71  5 (70) 73  6 (74) 33  13 (34) 0.007
Fractional shortness (%) 39  4 (38) 41  5 (41) 15  5 (16) 0.007
Cardiothoracic ratio in CXR 0.52  0.03 (0.52) 0.50  0.03 (0.51) 0.382
Laboratory data
CK (IU/l) 115  81 (68) 262  247 (123) 0.230
CK-MB (IU/l) 13  6 (14) 26  10 (25) 0.025
CRP (mg/dl) 1.66  1.43 (1.22) 1.13  0.84 (1.45) 0.635
Troponin I (ng/ml) <0.03 (<0.03) 3.84  4.84 (1.48) 0.001
BNP level (pg/ml) 3.8  2.4 (<5) 13.4  12.8 (9.5) 296.3  161.6 (238) <0.001
BNP z-score 1.52  0.88 (2.02) 0.37  1.45 (0.22) 6.33  0.94 (6.11) <0.001
BNP, B-type natriuretic peptide; CK, creatine kinase; CK-MB, MB fraction of creatine kinase; CRP, C-reactive protein; CXR, chest X-ray.
a Data are presented as mean  standard deviation (median).
b In the p-value column, the comparisons were performed among the groups by Kruskal–Wallis test, one-way analysis of variance (ANOVA) with post-hoc multiple
comparison Scheffe´ test, or Mann–Whitney U-test.
c Left ventricle end-diastolic internal dimension and left ventricle end-systolic internal dimension were adjusted for body surface area.
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sequelae. No group 3 patients had cardiomegaly on chest radiograms,
two patients had pulmonary edema, and all patients had poor left
ventricular systolic function with typical regional wall motion
abnormalities on echocardiography. Two patients in group 3 were
rescued by trans-sternal extracorporeal life support and were
successfully weaned off. All of the patients in group 3 survived
without cardiac complications, but one had mild weakness of the
upper limbs and dysphagia. Among the echocardiography studies,
there were no statistically signiﬁcant differences in adjusted LVEDd
among the groups, and no differences in adjusted LVEDs, EF, and FS
between group 1 and group 2. The patients in group 3 had
signiﬁcantly larger adjusted LVEDs (p = 0.015) and poorer EF
(p = 0.007) and FS (p = 0.007) than those in the other groups, as
shown in Figures 1 and 2.
The mean BNP value in group 1 was 3.8  2.4 pg/ml (ranging
from <5 pg/ml to 10.4 pg/ml, median <5 pg/ml), in group 2 was
13.4  12.8 pg/ml (ranging from <5 pg/ml to 54.5 pg/ml, median 9.5Figure 1. Adjusted left ventricular end-diastolic (A) and end-systolic (B) internal dimensi
analyzed statistically. Bars with the same letters are not signiﬁcantly different. C, normpg/ml), and in group 3 was 296.3  161.6 pg/ml (ranging from 172
pg/ml to 479 pg/ml, median 238 pg/mol). The BNP z-scores were
1.52  0.88 (median 2.02), 0.37  1.45 (median 0.22), and
6.33  0.94 (median 6.11), respectively, in the three groups. Results
are shown in Table 1. Patients in group 3 had signiﬁcantly higher
plasma BNP levels and BNP z-scores than those in the other groups
(p < 0.001 and < 0.001, respectively). Although there was no
statistically signiﬁcant difference in the plasma BNP values between
group 1 and group 2 (p = 0.612), patients in group 2 had signiﬁcantly
higher BNP z-scores than those in group 1 (p < 0.001). Among the three
groups, the lowest BNP z-score was in group 1 and the highest was in
group 3, as shown in Figure 3. Using a BNP value of 100 pg/ml or a BNP z-
score of 4.56 to determine the cut-off point for the identiﬁcation of
severe EV71 infection with acute heart failure and EF less than 50%, the
sensitivity, speciﬁcity, PPV, and NPV were all 100%. Using a BNP z-score
of 1.18 (BNP value of 15 pg/ml) to determine the cut-off point for the
detection of EV71 stage 2 infection, the sensitivity, speciﬁcity, PPV, and
NPV were 35%, 100%, 100%, and 70%, respectively.ons (LVEDd/LVEDs) categorized by different groups. Differences among groups were
al controls; EV-II, EV71 stage 2 patients; EV-III, EV71 stage 3 patients.
Figure 2. (A) Ejection fraction (EF), and (B) fractional shortness (FS) of the left ventricle categorized by different groups. Differences among groups were analyzed statistically.
Bars with the same letters are not signiﬁcantly different. ^, Outliers: cases with values that are between 1.5 and 3 box lengths from either end of the box. C, normal controls;
EV-II, EV71 stage 2 patients; EV-III, EV71 stage 3 patients.
Figure 3. (A) Plasma BNP values, and (B) plasma BNP standard deviation scores categorized by different groups. Differences among groups were analyzed statistically. Bars
with the same letters are not signiﬁcantly different. BNP, B-type natriuretic peptide; ^, outliers: cases with values that are between 1.5 and 3 box lengths from either end of
the box; *, extremes: cases with values more than 3 box lengths from either end of the box. C, normal controls; EV-II, EV71 stage 2 patients; EV-III, EV71 stage 3 patients.
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Children with EV71 infections usually only have oro-mucocu-
taneous lesions, but a few patients, less than 0.01%, progress to
severe EV71 infection. Subsequent acute cardiopulmonary failure
has been reported to occur in 11–19% of patients with severe EV71
infections, resulting in a mortality rate of 30–77% and severe
neurological sequelae.1–6,23,24 In this study, all three patients with
an EV71 stage 3 infection (group 3) had clinically typical ﬁndings,
such as normal heart size by chest X-ray and a regional wall motion
abnormality of the left ventricle that was identiﬁed as ‘panic or
shivering heart’ by echocardiography.25
For a biomarker to be valuable in clinical practice, it should be
rapidly and accurately measurable at a reasonable cost, add
diagnostic or prognostic information to available methods, and
help to guide patient management. BNP can fulﬁll most of these
criteria in patients with heart failure and ventricular overload.26
The Triage test system allows the widespread clinical use of BNP
determination, and recent studies have reported the usefulness of
BNP assessment in patients with various cardiovascular diseases,
including elevated plasma BNP concentrations in adults with heart
failure, systolic and diastolic dysfunction, or during different types
of hemodynamic overload of the heart. BNP has also been found to
be useful for distinguishing cardiac from non-cardiac respiratory
distress, to be correlated with the severity of heart failure
symptoms, and to predict hospital readmission and mortality.11–
20 However, the clinical application of plasma BNP in children whohave severe EV71 infections with or without acute heart failure
remains limited.
Although children with severe EV71 infections may experience
progression to acute heart failure, symptoms and signs suggestive
of heart failure are insensitive and non-speciﬁc for diagnosing
heart failure.1–7 The role of BNP testing is clearly deﬁned for
diagnosing patients with suspected myocardial stress who have
new symptoms of heart failure or acute respiratory distress, and for
assessing the prognosis of heart failure patients. In this study, the
preliminary results suggest the use of a BNP test to aid in the
diagnosis of children who have severe EV71 infections with
varying degrees of acute myocardial stress. Comparisons of the
echocardiography parameters, including LVEDd, LVEDs, EF, and FS,
with plasma BNP values or BNP z-scores, showed that there were
good correlations of myocardial dysfunction with plasma BNP
values and BNP z-scores. The plasma BNP values were markedly
elevated in patients with EV71 stage 3 infections.
In this study, a BNP value of 100 pg/ml was used as the cut-off
point for the detection of severe EV71 with acute heart failure,
which is similar to a previously recommended cut-off level for the
diagnosis of acute heart failure in adults.15 However, some
limitations of BNP testing have been noted for small elevations
of BNP in patients with cor pulmonale, mild ventricular dysfunc-
tion, and some congenital heart diseases with left-to-right shunts,
as well as in small children.19,26 Patients with chronic non-cardiac
diseases such as severe lung disease, impairment of renal function,
and diabetes may have higher BNP concentrations than those of
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age, and females have higher BNP values than males in the same
age strata. As children grow, BNP levels increase with a positive
and powerful linear correlation to age that reﬂects increasing
cardiac load.27 For the abovementioned reasons, plasma BNP
concentrations should be expressed as standard deviation scores
calculated according to age- and gender-speciﬁc normal values
using formulas.20
Although there was no signiﬁcant difference in plasma BNP
level between group 1 and group 2, there was a higher BNP z-score
in group 2 patients who did not actually have a clinical diagnosis of
heart failure. We propose that subclinical myocardial dysfunction
combined with myocardial stress may have occurred in these
patients, resulting in a mild elevation of the plasma BNP level.
Compared group 2 patients with group 3 patients and we found
that the BNP value was signiﬁcantly higher in patients with severe
EV71 infection and acute heart failure because the pressure loading
on their myocardium suddenly increased and the myocardium
failed to tolerate the high wall tension and stress. Thus, we used a
BNP z-score of 1.18 (an approximate BNP value of 15 pg/ml) as the
cut-off point for the identiﬁcation of EV71 stage 2 infection. The
sensitivity and speciﬁcity were 35% and 100%, respectively, which
suggests that a lower value of BNP may not be accurate enough to
rule out an EV71 stage 2 infection. Although the BNP z-score can be
derived from formulas, the BNP z-score would not be suitable in
routine clinical practice because it requires a more complex
calculation, so we suggest using a BNP value >15 pg/ml as a
predictor of EV71 stage 2 infection.
BNP is not a stand-alone test; it is of greatest value when it
complements clinical judgment along with other available tests,
such as cardiac troponins, CK-MB, and echocardiography. The use
of the BNP test in conjunction with other clinical information may
lead to more accurate and early diagnosis of severe EV71 infections
with acute myocardial stress.
Some limitations of this study need to be considered. In this
study mildly elevated plasma BNP values were found in EV71 stage
2 patients who did not actually have a clinical diagnosis of heart
failure. A control group of children with uncomplicated EV71
infections would have helped to clarify this situation. However, we
do not routinely isolate the virus and identify enteroviruses for
uncomplicated HFMD/herpangina patients. We will consider
enrolling uncomplicated EV71 infection patients as a control
group in a further study. Although we found plasma BNP values to
be signiﬁcantly elevated in children with severe EV71 infections
with acute heart failure, the number of children in group 3 was too
small to determine reference values. Further investigations of
plasma BNP levels detected at the different stages of EV71 infection
are needed to understand the trends in plasma BNP levels with
regard to disease progression and convalescence; large multi-
institutional studies are required.
In conclusion, our ﬁndings validate and extend the observations
made in a leading study using a BNP test, a powerful cardiac
biomarker, to aid in the diagnosis of children who have severe
EV71 infections with acute heart failure. The results of this study
suggest that rapid measurement of the BNP level in blood can
demonstrate the relationship of BNP levels with the severity and
speed of heart failure, and can improve the ability of clinicians to
establish whether or not children with severe EV71 infections have
acute heart failure. We speculate that a plasma BNP value >100 pg/
ml could identify children with severe EV71 infections who have
marked left ventricular dysfunction and who need further
evaluation as well as early interventions, such as extracorporeal
life support. In order to reach deﬁnitive conclusions regarding the
clinical utility of BNP as a biomarker of heart involvement in
children with severe EV71 infections, further investigations and
large multi-institutional studies are necessary.Acknowledgements
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